Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Subcommittee approves changes to January and February 2025 drug formularies; excludes Trintellix
Summary
Grant Wallace, director of the Employee Benefits Division, told the JBC-Employee Benefits Division—Oversight Subcommittee that the committee was reviewing standard formulary updates for January and February 2025 and recommended several exclusions and quantity-limit or tiering changes.
Grant Wallace, director of the Employee Benefits Division, told the JBC-Employee Benefits Division—Oversight Subcommittee that the committee was reviewing standard formulary updates for January and February 2025 and recommended several exclusions and quantity-limit or tiering changes.
Wallace said the changes affect both pharmacy-dispensed medicines and drugs administered in clinical settings. "These are our normal formularies that you all, in ALC review, so now you get the pleasure of doing so today," he said. He added that most changes are related to "quantity limits, or some tiering updates" and that some newer products are being excluded "until there is more clinical evidence of the efficacy and value of adding them on."
The subcommittee heard two exclusion items…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
